FT : Palladium set to close at 3-year high as demand surges

The price of palladium, a precious metal used to control harmful vehicle emissions, jumped on Friday, is on course to close at a three year high on Friday as investors piled in.

The precious metal rose by as much as 7 per cent to $917.40 an ounce, extending gains since the start of the year to 30 per cent, making it one of the best-performing commodities.

Analysts pinned the latest gains on a combination of factors: strong demand, rising investor interest and constrained supplies.

“Perhaps there isn’t one big explanation or a specific catalyst that has led to the recent market moves, but rather confluence of factors that have actually been brewing (and market participants) have been discussing for a while,” said Joni Teves, analysts at UBS.

Investors are warming to platinum because of shifts in the car market. Gasoline and hybrid vehicles, fitted with palladium-rich catalytic convertors, are becoming increasingly more popular with consumers.

At the same time, buyers are turning their backs on diesel-powered vehicles, which used platinum-rich autocatalysts. This is because they are worried about possible legislation changes in the wake of the Volkswagen emissions scandal.

That in turn has weighed on platinum, which has gained just 4 per cent since the start of the year and is currently at $940 an ounce. The last time the two metals traded at parity was in 2001.

*WTO POSTS U.S.-EU RULING ON AIRCRAFT SUBSIDIES ON WEBSITE

We conclude that:
a.
To the extent that we have ruled that the European Union's claims under Articles 3.1(a),
3.1(b) and Article 3.2 of the SCM Agreement
are within the scope of this proceeding,
these claims are unfounded because: (i) certain measures challenged by the
European Union are not subsidies provided to
Boeing after the end of the implementation
period; and (ii) where we find that the measures at issue are subsidies provided to
Boeing after the end of the implementation
period, the European Union has failed to
establish that any of these subsidies is contingent in fact upon export performance or
upon the use of domestic over imported goods.
b.
To the extent that we have ruled that the European Union's claims under Article III:4 of
the GATT 1994 are within the scope of this proceeding, the European Union has failed to
establish that any of the measures at issue is inconsistent with Article III:4 of the
GATT 1994.

>>> Goldman Sees MiFID Equities Headwinds, Some Offsets: Nomura

Goldman Sees MiFID Equities Headwinds, Some Offsets: Nomura
-
Key focus in equities business during Nomura Instinet meeting with Goldman CFO Marty Chavez earlier this week was on potential impact from new European trading rules called MiFID II (Markets in Financial Instruments Directive), analyst Steven Chubak writes in note recapping meeting.
  • Chavez noted expectations for severe downward rev. pressure with any regulatory/market structure change over the years (like Regulation NMS, decimalization); said MiFID II is no different
    • At the same time, rev. headwinds have generally been at least partly offset by opportunities; for example, shift from active to passive hurt equity commissions but also prompted new products
    • Chavez said GS scale, differentiated content position firm well
  • Messaging at meeting suggests GS is starting to focus on growth after prioritizing control levers (capital, expense mgmt), which may have dragged on rev./pricing; progress may be obscured by challenging 2Q; GS acknowledged recent FICC weakness raises questions about appropriate balance between control and growth
    • Chavez highlighted growth prospects in number of areas, including Marcus (room for further loan growth), consumer adjacencies, other tech-focused opportunities, like providing data analytics to clients, recent investment in quant fund offerings
  • GS up as much as 2.1% to highest intraday since May 26 while S&P 500 financials (S5FINL) gains as much as 1.5% to highest since March 21, KBW banks index (BKX) rises 2% to highest since May 9

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • DTRM +7.8%, ASNA +5.8%, ARIS +4.5%, LMNR +4.2%, OESX +3.7%, KMG +2.3%, LAYN +0.8%
M&A news:
  • DFT +15.5% (DFT will merge with Digital Realty (DLR) in an all-stock transaction), DLR +1.9%
  • ADHD +12.4% (vague M&A chatter)
  • DISH +2.4% (renewed AMZN M&A chatter circulates)
Other news:
  • ONCS +7.1% (confirms being granted Orphan Drug Designation for pIL-12 for the treatment of unresectable metastatic melanoma )
  • COLL +5.1% (following Opana ER news; also will present data on Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 2017 International Conference on June 11-12)
  • LXRX +4.8% (announces positive top-line results from its Phase 3 inTandem3 study of sotagliflozin for the treatment of patients with type 1 diabetes on any background insulin therapyg)
  • P +3.3% (SiriusXM (SIRI) to make a $480 mln strategic cash investment in Pandora)
  • INO +3.3% (CEO featured on Thursday's Mad Money)
  • IIVI +2.3% (is ramping up production of 18 W pump laser diodes for fiber lasers; will double production capacity by the end of this year)
  • OHI +2% (appointed Craig R. Callen as Chairman)
  • AGTC +2% (Applied Genetic Technologies to present topline safety data for dose escalation phase of its Ph 1/2 X-linked retinoschisis clinical trial at Macula Society Annual Meeting in Singapore on June 10 )
  • AMD +1.6% (scontinued strength)
  • AAL +0.5% (May Traffic)
Analyst comments:
  • ZNGA +3.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
  • NVDA +2.3% (target raised to $175 from $140 at Argus)
  • CWH +2.1% (upgraded to Buy from Neutral at Goldman )
  • C +0.7% (upgraded to Neutral from Sell at UBS )
  • PYPL +0.7% (target raised to $62 from $52 at Citigroup)
  • ADBE +0.6% ( target raised to $160 from $140 at BMO Capital Markets)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • CLDR -14.2%, ATU -5.9%, PAY -4.2%, HNI -2%, (HNI lowers Q2 revenue and earnings expectations on slower than anticipated sales in office furniture business), FGP -2%,XTLY -0.6%
Select UK based names showing weakness following UK elections:
  • RBS -3.6%, BT -3%, BCS -2.3%, LYG -2.2%, NGG -1.9%, GWPH -1.8%, AZN -1.1%, GSK-0.8%, PUK -0.8%
Other news:
  • EYEG -16.1% ( prices 6,666,667 shares of common stock and warrants at $1.50 per share of common stock)
  • ENDP -12.9% (FDA requests removal of Opana ER for risks related to abuse; co is reviewing the request and evaluating the full range of potential options )
  • MRCC -3.4% (commences an underwritten public offering of shares of its common stock)
  • ACGL -2.5% (prices secondary common stock offering of 6.4 mln shares, at $92.50/share)
  • CUR -2.4% (thinly traded - files for $100 mln mixed securities shelf offering)
  • DEPO -2% (following ENDP FDA news)
  • INSY -1.7% (following ENDP FDA news)
  • CAA -0.9% (prices Secondary offering by selling shareholders consisting of 42,842,557 shares of common stock at $34.25 per share)
Analyst comments:
  • TOO -14.4% (downgraded to Underweight at Morgan Stanley )
  • TK -11.2% (downgraded to Underweight at Morgan Stanley )
  • SNAP -1.9% (downgraded to Neutral from Buy at Citigroup)
  • DPZ -1.4% (downgraded to Neutral from Buy at Longbow)
  • TECK -1.3% (downgraded to Neutral from Buy at BofA/Merrill)
  • SHPG -1.1% (target lowered to $216 from $239 at Jefferies )